https://www.selleckchem.com/pr....oducts/pqr309-bimira
The potential association between receipt of direct-acting antiviral (DAA) therapy for chronic hepatitis C infection (HCV) infection and the development of de-novo or aggressive progression of hepatocellular carcinoma (HCC), surprisingly, continues to be debated, more than 3 years after first being raised in small single-center observational studies1,2,3 . After initial studies without a concurrent control group described both an increased incidence of de-novo HCC as well as more aggressive recurrence after curative anticance
Like
Comment
Share
